(-0.09%) 5 044.25 points
(-0.12%) 37 961 points
(-0.22%) 17 509 points
(-0.70%) $82.15
(-0.74%) $1.744
(-0.19%) $2 393.40
(-0.39%) $28.27
(-1.74%) $937.90
(-0.13%) $0.938
(-0.15%) $11.02
(-0.12%) $0.803
(-0.67%) $93.27
5 days till quarter result
(bmo 2024-04-24)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer...
Stats | |
---|---|
Today's Volume | 27 081.00 |
Average Volume | 54 621.00 |
Market Cap | 247.10M |
EPS | €0 ( 2023-11-13 ) |
Next earnings date | ( €0 ) 2024-04-24 |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | -3.12 |
ATR14 | €0.0260 (0.50%) |
Volume Correlation
Nanobiotix SA Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Nanobiotix SA Correlation - Currency/Commodity
Nanobiotix SA Financials
Annual | 2022 |
Revenue: | €4.78M |
Gross Profit: | €3.28M (68.59 %) |
EPS: | €-1.640 |
Q2 | 2023 |
Revenue: | €3.29M |
Gross Profit: | €3.29M (100.00 %) |
EPS: | €-0.800 |
Q4 | 2022 |
Revenue: | €3.45M |
Gross Profit: | €2.69M (78.13 %) |
EPS: | €-0.880 |
Q2 | 2022 |
Revenue: | €1.33M |
Gross Profit: | €583 000 (43.87 %) |
EPS: | €-0.760 |
Financial Reports:
No articles found.
Nanobiotix SA
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators